Tag: Nk3 receptor antagonist

On May 12, 2023, the U.S. Food and Drug Administration (FDA) approved Veozah (fezolinetant) as a new prescription medication. This landmark decision provided a non-hormonal treatment option for women experiencing moderate to severe vasomotor symptoms (VMS), also known as hot flashes, due to menopause.

Affecting up to 80% of menopausal women, hot flashes can disrupt daily life and sleep. For those considering non-hormonal treatment, understanding **how quickly does Veozah take effect** is key to managing expectations and evaluating its efficacy in managing moderate to severe vasomotor symptoms.

Veozah, the brand-name medication with the active ingredient fezolinetant, was approved by the FDA in May 2023 for treating moderate to severe hot flashes due to menopause. As of late 2025, there is **no generic for Veozah** available on the market.

Approved by the FDA in 2023, Veozah (fezolinetant) is a non-hormonal treatment for hot flashes associated with menopause. A common question for many patients is, **is there a generic version of Veozah?** The short answer is no, and the reasons lie in the drug's recent approval and current patent protection.

Roughly 80% of women experience vasomotor symptoms like hot flashes and night sweats during menopause. In response, a significant advancement offers a new treatment for hot flashes: the non-hormonal drug Veozah (fezolinetant), approved by the FDA in 2023. This represents a major breakthrough, particularly for those who cannot or prefer not to use hormone replacement therapy.